- A federal appeals court has significantly restricted access to mifepristone, a common abortion medication, by blocking its distribution through the mail.
- The New Orleans-based 5th U.S. Circuit Court of Appeals now mandates that the abortion pill be dispensed solely in person at clinics.
- The ruling asserted that the FDA's actions facilitating abortion undermined Louisiana's policy recognizing an unborn child as a legal person from conception.
- This decision marks a departure from the historical judicial deference typically given to the Food and Drug Administration's judgments on drug safety and regulation.
- The ruling sets the stage for a likely appeal to the Supreme Court, which previously preserved access to mifepristone in 2024 by sidestepping core legal issues.
IN FULL
